


Journal Pre-proof

Efficacy of hemostatic agents in endodontic surgery: A systematic review and network meta-analysis

Ahmad G.A. Khater , Faez Saleh Al-hamed , Engie M. Safwat ,
Mehada M.A. Hamouda , Mohamed S.A. Shehata ,
Antonio Scarano

PII: S1532-3382(21)00015-4
DOI: <https://doi.org/10.1016/j.jebdp.2021.101540>
Reference: YMED 101540



To appear in: *The Journal of Evidence-Based Dental Practice*

Received date: 14 January 2021
Revised date: 16 February 2021
Accepted date: 20 February 2021

Please cite this article as: Ahmad G.A. Khater , Faez Saleh Al-hamed , Engie M. Safwat , Mehada M.A. Hamouda , Mohamed S.A. Shehata , Antonio Scarano , Efficacy of hemostatic agents in endodontic surgery: A systematic review and network meta-analysis, *The Journal of Evidence-Based Dental Practice* (2021), doi: <https://doi.org/10.1016/j.jebdp.2021.101540>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Elsevier Inc. All rights reserved.

1 Efficacy of hemostatic agents in endodontic surgery: A systematic review and network meta-analysis

2 Ahmad G. A. Khater^{a,*}, ahmed.g.a.khater@gmail.com, Faez Saleh Al-hamed^b, Engie M. Safwat^c, Mehada
3 M. A. Hamouda^d, Mohamed S. A. Shehata^e, Antonio Scarano^{f,g}

4 ^aFaculty of Oral and Dental Medicine, Ahram Canadian University, Egypt

5 ^bFaculty of Dentistry, McGill University, Montreal, QC, Canada

6 ^cRestorative and Dental Materials Department, National Research Centre, Egypt

7 ^dFaculty of Dentistry, Misr University of Science and Technology, Egypt

8 ^eFaculty of Medicine, Zagazig University, Zagazig, Egypt

9 ^fDepartment of Medical, Oral and Biotechnological Sciences and Center for Advanced Studies and
10 Technology (CAST), University of Chieti-Pescara, Chieti, Italy

11 ^gResearch staff at Zirconia Implant Research Group (Z.I.R.G), International Academy of Ceramic
12 Implantology, Silver Spring, MD, USA

13 *Corresponding author: Faculty of Oral and Dental Medicine, Ahram Canadian University, 4th Industrial
14 Zone, Banks Complex, 12451 6th of October city, Giza, Egypt

15 Abstract

16 **Objective:** Adequate hemostasis is a critical step in endodontic surgery. It facilitates the procedure
17 and affects the success and prognosis of the operation. This systematic review and network meta-
18 analysis (NMA) aimed to systematically assess the efficacy of hemostatic agents in endodontic
19 surgery and to identify the most effective.

20 **Methods:** PubMed, Scopus, Embase, Cochrane Library, Web of Science, ProQuest, and EBSCOhost
21 databases were searched up to December 2020. We included randomized controlled trials (RCTs)
22 evaluating the efficacy of different hemostatic measures in endodontic surgery, and their risk of bias
23 was assessed using Cochrane's randomized trial tool (RoB 2.0). Frequentist network meta-analysis
24 was conducted, with Odds Ratios and 95% confidence intervals (OR, 95% CI) as effect estimates
25 using the "netmeta" package in R. The quality of evidence was assessed using the CINeMA approach.

1 **Results:** Six RCTs involving 353 patients (mean age 48.12 years) were included. NMA revealed that
2 aluminum chloride achieved higher hemostatic efficacy than epinephrine (OR= 2.55, 95% CI [1.41,
3 4.64]), while there was non-significant difference when compared with PTFE strips+ epinephrine
4 (OR= 1.00, 95% CI [0.35, 2.90]), electrocauterization (OR= 2.67, 95% CI [0.84, 8.46]), or ferric
5 sulfate (OR= 8.65, 95% CI [0.31, 240.92]). Of all hemostatic agents, aluminum chloride ranked first
6 in control bleeding during endodontic surgery (P-score= 0.84), followed by PTFE strips+ epinephrine
7 (P-score= 0.80), electrocauterization (P-score= 0.344), epinephrine (P-score= 0.34), ferric sulfate (P-
8 score= 0.18). The quality of evidence was very low.

9 **Conclusions:** Based on the limited data, aluminum chloride provides better hemostasis than
10 epinephrine, while there was no significant difference between the remaining hemostatic agents used
11 in endodontic surgery, which could help clinicians achieve adequate hemostasis and give insight to
12 future RCTs. Given insufficient evidence, future RCTs addressing this **evidence** gap are required.

13
14
15 **Keywords:** *Bleeding, Endodontic surgery, Evidence-based dentistry, Hemostasis, Hemostatic agent,*
16 *Network meta-analysis.*

17 **Introduction**

18 Endodontic surgery is an alternative surgical procedure aimed to preserve the necrotic tooth when
19 conventional root canal treatment is failed or cannot be performed^{1, 2}. It provides surgical access to the
20 contaminated apical part of the root, followed by removing the associated extra-radicular infection and
21 placing a retrograde filling to adequately seals the root canal system and prevent the leakage between the
22 root canal system and the extra-radicular tissues³.

23 According to the European Society of Endodontology, endodontic surgery is indicated for the following
24 conditions: 1) radiographic symptoms of periapical lesions associated with obstructed canals, 2) clinical
25 or radiographic signs associated with extruded material, 3) persistent pathology that cannot be treated
26 with conventional root canal therapy, and 4) root perforation that is not accessible through the coronal
27 root opening⁴. **Endodontic surgery's success** is based on many factors, including proper diagnosis,
28 appropriate case selection, operator skills, accurate management of the soft and hard tissues, and apical
29 seal^{3, 5, 6}.

1 Adequate hemostasis is a critical step during endodontic surgery. It facilitates the procedure and improves
2 the success and prognosis of the surgery^{7, 8}. In the absence of adequate hemostasis, bleeding will obscure
3 the anatomical landmarks and reduce vision^{9, 10}. Also, adequate hemostasis provides a dry field at the
4 surgical site, **improving** the surgery's quality by facilitating the surgical procedure, reducing time, and
5 decreasing post-surgical complications such as hemorrhage, swelling, and reducing patient pain during
6 surgery¹¹⁻¹³. Also, it provides a suitable environment to place the moisture-sensitive retrograde filling
7 materials¹⁴.

8 The ideal hemostatic agent should be biocompatible, easy to apply, has an immediate effect, does not
9 adversely affect the healing process, and relatively inexpensive⁹. Several agents have been used to
10 control bleeding, including cotton and gauze, bone wax¹¹, collagen-based products^{3, 12}, a mixture of
11 surgical wax and fibers of calcium alginate¹⁵, vasoconstrictors (e.g., epinephrine)^{16, 17}, calcium sulfate¹⁴,
12 ferric sulfate^{16, 18}, aluminum chloride^{8, 19-22}, and electrocauterization²⁰. However, many hemostatic
13 agents have been used to control bleeding during endodontic surgeries, there is no universal consensus
14 regarding selecting the best hemostatic agent, and the choice is usually based on the operator's preference.
15 In order to address this knowledge gap, we performed a systematic review with network meta-analysis
16 (NMA) summarizing the efficacy of the available bleeding control measures used in endodontic surgery.

17 The role of NMA in informing clinicians and decision-makers **is** becoming more prominent, as many
18 health conditions have many competing treatments, and the meta-analysis (pairwise) is limited to provide
19 a direct comparison of only two interventions by using a statistical combination of the results. The NMA
20 provides comparisons between multiple treatments by integrating direct and indirect estimates to
21 determine the best based on ranking their probability of having significant effects²³⁻²⁵. Therefore, NMA
22 seemed to be the highest level of evidence in treatment recommendations and decision-making^{26, 27}.
23 Many NMA has been performed in endodontics to overcome the knowledge gap in specific topics, such
24 as local anesthesia²⁸⁻³⁰ and the safety and efficacy of drugs used in non-surgical endodontics procedures
25^{31, 32}. To our knowledge, this is the first meta-analysis investigating the effectiveness of hemostatic agents
26 in endodontic surgery and aimed to answer the following question: what is the most effective hemostatic
27 agent used in endodontic surgery?

28 **Methods**

29 **Protocol and registration**

1 This study follows the PRISMA guidelines for reporting systematic reviews incorporating network meta-
2 analyses of health care interventions ³³, and protocol has been registered in the INPLASY database (No.
3 INPLASY202120038) ³⁴.

4 *Eligibility criteria*

5 We constructed the inclusion criteria based on the PICO process as the following: P: Patients requiring
6 endodontic surgery, I: Aluminum chloride, C: Other types of hemostatic measures (PTFE strips +
7 epinephrine, electrocauterization, epinephrine, and ferric sulfate), O: Bleeding control. Since transitivity
8 (validity of indirect comparisons) is highly influenced by randomization, we included only randomized
9 controlled trials that assessed the efficacy of hemostatic agents in endodontic surgery without time or
10 language restrictions ^{24, 25}. Exclusion criteria were non-randomized clinical trials, observational studies,
11 animal studies, in-vitro studies, case reports and series, reviews, book chapters, and personal opinions.

12 *Information sources and search*

13 A comprehensive electronic search was conducted using the following databases: PubMed, Scopus,
14 Embase, Cochrane Library, Web of Science, as well as ProQuest and EBSCOhost for grey literature. The
15 final search was updated on December 20, 2020. Besides, the Journal of Endodontics, International
16 Endodontic Journal, and Australian Endodontic Journal were searched. The reference lists of pertinent
17 reviews on the subject were checked for possible additional studies. Appendix Table S1 illustrates the
18 detailed search strategy that has been implemented.

19 *Study selection*

20 Two independent evaluators (AK, MH) conducted the literature search and screened the articles. If the
21 agreement was not achieved, a third researcher should resolve the disagreement (AS).

22 *Data collection*

23 Two independent evaluators (AK, ES) collected the following data for each study: authors, year of
24 publication, country, study design, study setting (location and operator), sex (male: female), mean age,
25 medical condition, number of patients in each group, results relevant to hemostatic efficacy, and funding
26 source. Any disagreement was resolved by the third author (AS).

27 *Quality assessment*

28 Quality assessment of the included studies was performed by two independent authors (AK, FA)
29 following the Cochrane risk of bias tool for randomized trials (RoB 2.0) ³⁵. Any disagreement was

1 resolved by discussion. This tool has five domains: risk of bias due to the randomization process,
2 deviations from the intended interventions, missing outcome data, measurement of the outcome, and
3 selection of the reported results.

4 Quality of studies was classified as a low risk of bias if all five domains have no risk of bias, some
5 concerns risk of bias if there is one or more of the domains have an unclear risk of bias, or high risk of
6 bias if one of the domains has a high risk of bias. We used the "robvis" package to display the risk of bias
7 assessment³⁶.

8 *Data synthesis*

9 Pairwise meta-analysis was performed to assess all direct comparisons between different hemostatic
10 agents using the random effect model (RevMan version 5.3- Cochrane collaboration). Frequentist network
11 meta-analysis (NMA) was implanted using the statistical package "netmeta"^{37, 38} in the R program
12 (version 4.0.2)³⁹. Dichotomous data were pooled as the odds ratio (OR) with a 95% confidence interval
13 (CI). Significant differences were considered when the 95% CI did not include 1 for OR. Heterogeneity
14 was defined as the variability of results across studies, in which $I^2 < 50\%$ indicates low heterogeneity, and
15 $I^2 \geq 50\%$ indicates significant heterogeneity. Studies were compared using a random effect model.
16 Inconsistency between direct and indirect estimates was assessed by net-split function in the "netmeta"
17 package and measured by generalized Cochran's Q statistics for multivariate meta-analysis as described
18 by Krahn and his colleagues⁴⁰. Depending on the point estimates and standard errors of the estimated
19 frequentist network meta-analysis, P-score was used to rank the treatments, in which a higher value
20 indicates better performance. P-scores calculate the degree of confidence, indicating that one treatment is
21 better than the other, which is an average for all comparable treatments⁴¹.

22 *Confidence of evidence*

23 The certainty of cumulative evidence was evaluated using the Confidence in Network Meta-Analysis
24 (CINeMA) approach⁴²⁻⁴⁴. The confidence was graded as "high," "moderate," "low," or "very low" based
25 on the following domains: study limitations, publication bias, indirectness, imprecision, heterogeneity,
26 and incoherence.

27 **Results**

28 *Study selection*

29 The electronic and manual searches identified (n=1,938) articles, of which (n=57) were excluded because
30 of duplication. The remaining (n=1,863) articles were screened by titles and abstracts, of which (n=1,833)

1 articles were excluded as irrelevant. The full-texts of 30 studies were reviewed; six studies met the
2 inclusion criteria ^{8, 16, 19-22}, while the other 24 articles were excluded because they did not meet the
3 inclusion criteria ^{7, 9, 11-15, 17, 45-58}. (Figure 1 and Appendix Table S2)

4 *Study characteristics*

5 Six RCTs were included in this systematic review ^{8, 16, 19-22}. The total number of participants included was
6 353 patients (mean age 48.12 years), including both genders. Surgeries were performed in the esthetic
7 maxillary zone ²⁰, the maxillary or mandibular areas (anterior to the 2nd premolars) ²¹, and the posterior
8 maxillary zone (first and second molars) ²². Peñarrocha-Oltra et al. ²⁰ included a single tooth in the
9 esthetic zone (upper incisors, canines, and premolars), while Peñarrocha-Oltra et al. ²¹ included one or
10 two contiguous teeth, either maxillary or mandibular between the right to left second premolars, whereas
11 excluded multi-rooted posterior teeth. The remaining studies included both maxillary and mandibular
12 teeth. Table 1 presents a summary of the main characteristics of the included studies.

13 *Risk of bias within studies*

14 Overall, five studies ^{8, 19-22} were considered to have some concerns risk of bias, and one study ¹⁶ was
15 considered to have a high risk of bias.

16 The study by Vickers et al. was assessed as a high risk of bias because it has some concerns in multiple
17 domains. It has some concerns in the first domain (*Bias arising from the randomization process*) due to
18 no details about the allocation concealment, in the second domain (*Bias due to deviations from the*
19 *intended interventions*), **fourth** domain (*Bias in the measurement of the outcome*) due to no information
20 about the blinding process, and in the fifth domain (*Bias in the selection of the reported result*) because
21 no protocol found ¹⁶.

22 Five studies ^{8, 19-22} were identified as some concerns risk of bias as all of them had a low risk of bias in all
23 domains except in the fifth domain (*Bias in the selection of the reported result*) because we did not find
24 protocols in all of them to compare them with the reported results. Figure 2 summarizes the quality
25 assessment of the included studies.

26 *Hemostatic efficacy*

27 In all studies, the surgical operator determined the efficacy of hemostatic agents. All included studies
28 identified adequate hemostasis as complete control of bleeding that provides a dry surgical area during the
29 root-end filling process. However, there was a variation in the definition of inadequate hemostasis,
30 described by three studies as no hemorrhage control (i.e., persistent bleeding that impaired vision in the

1 surgical field)^{8, 16, 20}. The other studies defined it as minor intermittent bleeding that continues after using
2 the hemostatic material (i.e., that permitted the root-end filling procedure)^{19, 21, 22}. (Table 1)

3 *Presentation of network geometry*

4 The comparisons between different hemostatic agents included five interventions (20% ferric sulfate,
5 epinephrine, aluminum chloride, electrocauterization, PTFE strips+ epinephrine. Since aluminum chloride
6 is the most common agent used in RCTs, it was contrasted with all available therapies, resulting in five
7 comparisons, as shown in the network graph. (Figure 3)

8 *Pairwise meta-analysis*

9 The pooled estimate of direct comparisons showed that aluminum chloride had higher hemostatic efficacy
10 compared to epinephrine (OR= 2.55, 95% CI [1.41, 4.64], P=0.002) with no heterogeneity ($I^2=0\%$,
11 $P=0.87$), and electrocauterization (OR= 2.67, 95% CI [0.84, 8.46], P=0.10). Whereas there is no
12 significant difference in control bleeding between aluminum chloride and PTFE strips + epinephrine
13 (OR= 1.00, 95% CI [0.35, 2.90], P=1.00) with no heterogeneity ($I^2=0\%$, P=0.59), as well, between
14 epinephrine and ferric sulfate (OR= 3.39, 95% CI [0.13, 89.37], P=0.14). (Figure 4)

15 *Network meta-analysis*

16 The network estimate revealed that aluminum chloride achieved higher hemostatic efficacy than
17 epinephrine (OR= 2.55, 95% CI [1.41, 4.64]). However, there is no substantial change in control bleeding
18 when compared aluminum chloride with PTFE strips+ epinephrine (OR= 1.00, 95% CI [0.35, 2.90]),
19 electrocauterization (OR= 2.67, 95% CI [0.84, 8.46]), and ferric sulfate (OR= 8.65, 95% CI [0.31,
20 240.92]). The heterogeneity of the network meta-analysis was not significant (Cochran's $Q=0.32$, $p=0.85$,
21 $\tau^2=0$, $\tau=0$, $I^2=0\%$ [0.0%; 35.2%]). (Table 3 and Appendix Figure S1)

22 *Treatments' ranking*

23 The ranking P-score showed that aluminum chloride was the best hemostatic agent (P-score= 0.84),
24 followed by PTFE strips+ epinephrine (P-score= 0.80), electrocauterization (P-score= 0.344), epinephrine
25 (P-score= 0.34), ferric sulfate (P-score= 0.18). (Appendix Table S3)

26 **Publication bias**

27 **Given the limited number of included studies (less than ten studies), the publication bias assessment by**
28 **comparison-adjusted funnel plot was not applicable⁵⁹. (Appendix Figure S2)**

1 *Quality of evidence*

2 Due to the limited number of studies included and the small sample, the evidence's certainty was mainly
3 decreased due to incoherence and imprecision. The quality of cumulative evidence was very low for all
4 comparisons. Details of rating the quality of evidence were summarized in Table 4. (Appendix Figure S3)

5 **Discussion**

6 In this study, we systematically assessed the available evidence regarding the efficacy of various
7 hemostatic measures to control bleeding in endodontic surgery. We found that aluminum chloride was
8 more effective than epinephrine in control bleeding, while there was no significant difference between the
9 remaining hemostatic agents used in endodontic surgery. Overall, there is very little evidence about
10 bleeding control during endodontic surgery, as we identified only six RCTs, mainly from Spain. Most of
11 the included studies were of high quality; however, all RCTs (except for one study⁸) and even non-
12 randomized trials assessed the efficacy of hemostatic agents during surgery without evaluating their
13 adverse effects, postoperative complications, or healing potential, that may affect the body of evidence on
14 the choice of hemostatic interventions. Therefore, we cannot recommend using a specific hemostatic
15 agent during endodontic surgery.

16 Aluminum chloride (AlCl₃) is widely used as a hemostatic agent because it is clinically effective, easy to
17 apply, cheap, and commercially available. The effectiveness of aluminum chloride to control bleeding
18 during endodontic surgery is well-documented in the literature^{8, 19-22, 50, 57}. It reacts chemically with blood
19 proteins and is distinguished by its acidic properties. These characteristics make it a suitable hemostatic
20 agent due to the blood's high protein content⁶⁰. Aluminum chloride acts by creating a barrier formed by
21 the coagulated blood proteins that prevent blood flow from the arteries, thus preventing its possible
22 systemic side effects. This mechanism may provide sufficient hemostasis, even in patients with bleeding
23 disorders^{60, 61}.

24 On the other hand, aluminum chloride is a paste-based agent that causes the substance to adhere to bony
25 crypt walls, making it difficult to remove its remnants⁵³. Animal studies have shown a marked
26 inflammatory response associated with the residuals particles that cause localized foreign body reactions
27 and may delay healing^{50, 53, 57}. Although it is easy to wash with saline since it is hydrophilic, it is still not
28 recommended due to the possibility of leaving traces in the cancellous bone⁵⁷. Such complications can be
29 wholly eliminated by cleaning the surgical site with a bone curette and freshening the bone defect is using
30 a small round bur, and filling the root end with a filling material such as mineral trioxide aggregate
31 (MTA) to avoid direct contamination by water spray^{8, 50, 57}. Besides, studies found that patients treated

1 with aluminum chloride had better healing after one year compared to epinephrine, but the difference was
2 not significant^{7,8}.

3 To overcome this limitation, there is a strong need for materials that achieve adequate hemostasis during
4 endodontic surgery and can also be removed easily or resorbed physiologically without complications,
5 particularly in the posterior areas where the complete removal of remnants is more difficult. Peñarrocha-
6 Oltra et al. first proposed the use of PTFE strips as an addition to epinephrine-impregnated gauze in
7 endodontic surgery^{21, 22}. PTFE is characterized by many features that make it a good option to use in
8 endodontic surgery^{62, 63}. PTFE is relatively inert, making it biocompatible without allergic reactions, and
9 has low surface energy, **which** leads to a very low coefficient of friction that means that it can be removed
10 without any residuals^{64, 65}. Also, it has high thermal stability, rendering it autoclavable without impacting
11 its physical characteristics⁶³. Consequently, the application of PTFE as an adjunct to epinephrine acts as a
12 mechanical barrier to control bleeding in the surgical site, as well as provides good handling efficiency in
13 treating areas around bleeding anatomical structures (e.g., maxillary sinus) and complicated anatomical
14 features (e.g., multi-rooted teeth)^{21, 22}. Based on this NMA, PTFE strips + epinephrine is the second-
15 ranked in control bleeding during endodontic surgery, but this ranking should be viewed cautiously.

16 On the other side, calcium sulfate (CaS), also known as "Plaster of Paris," acts mechanically by serving as
17 a physical barrier to achieving hemostasis^{46, 66}. It is a distinctive agent that is inexpensive, fast set, and
18 easy to remove and apply⁶⁷. CaS is characterized by excellent biocompatibility with no adverse effects on
19 outcomes, lack of inflammatory reactions^{45, 53}, **and** some debates about whether it may improve healing
20^{45, 53, 67, 68}. Also, it is completely resorbable and does not impair the MTA's function, which ensures that it
21 can be removed or left in-situ without any concerns and no risk of use near bleeding anatomical structures
22 (e.g., maxillary sinus)^{45, 53, 67-69}. The hemostatic efficacy of CaS was clinically assessed and was about
23 100% effective in controlling bleeding during endodontic surgery¹⁴. The CaS was used as a hemostatic
24 agent after dental extraction in patients undergoing anticoagulant therapy⁷⁰ and for control of bleeding
25 during surgical-exposure of impacted teeth prior to orthodontic treatment⁷¹. Although CaS was not
26 included in **this study** since the only clinical trial evaluated was a non-randomized trial¹⁴, we recommend
27 considering it for potential RCTs due to its distinctive characteristics **in different clinical situations**.

28 Epinephrine is one of the most common hemostatic agents used in endodontic surgery. It stimulates the
29 alpha-adrenergic receptors that cause vasoconstriction, and it has the least cytotoxic effect^{13, 56}.
30 Consequently, applying a cotton pellet or gauze impregnated with epinephrine will act by the chemical
31 action of epinephrine and the mechanical action of a cotton pellet or gauze¹⁰. As a result, there is a risk of
32 traces of fibers at the surgical site that may delay healing through inflammation and foreign body

1 reactions⁷². Therefore, it is recommended to remove it carefully followed by rigorous irrigation¹⁰. Also,
2 there have been some questions about the use of vasoconstrictors (e.g., epinephrine) as a local hemostatic
3 agent that can exert systemic cardiovascular effects in addition to its use in local anesthesia^{13, 73, 74}.
4 Clinical studies have denied these concerns in healthy patients and have shown that epinephrine has
5 reasonable hemostatic efficacy without changes in pulse rate or blood pressure^{16, 17}.

6 Electrocauterization is a useful tool for achieving hemostasis by exerting an electrical heat, which causes
7 blood and tissue proteins to coagulate and prevents blood flow, leaving an eschar that the body is trying to
8 slough^{50, 75}. As such, no foreign substance is inserted into the bony crypt with this method⁵⁰. However,
9 there was a concern about the effect on healing due to the thermal damage to the bone tissue⁷⁶. Jensen et
10 al. showed delayed healing, signs of superficial necrosis with minimal bone formation, and an adverse
11 tissue reaction related to necrotic zones were observed in the initial healing process⁵⁰. To avoid the
12 potential complications, coagulum tissues should be removed with a bone curette and freshened the
13 superficial bone layer with a rotary instrument to minimize the adverse tissue reactions⁵⁰.

14 Ferric sulfate (FS) is a necrotizing agent with very low pH (0.8-1.6)⁷⁷, as it acts chemically by interacting
15 with blood proteins leading to coagulation^{18, 75}. It is easy to use, inexpensive, has been reported to
16 achieve hemostasis in less than 1 min, and sustained for up to 5 min^{18, 78}. However, it is cytotoxic^{53, 56},
17 and when used in maximum concentrations and left in situ, results in bone damage, extreme foreign body
18 reactions, and abscess formation^{18, 78}. Also, it could induce mild foreign body reactions but did not hinder
19 bone healing^{57, 78}. Accordingly, complete removal must be due to potential inflammatory reactions
20 associated with its remains^{53, 57, 78}. Ferric sulfate coagulum can be easily removed using a curettage and
21 saline irrigation⁷⁸.

22 This study has some limitations; the first is the small sample size and the restricted number of included
23 studies. Second, the included studies did not assess the influence of hemostatic agents on healing, long-
24 term success rates, and patient-reported outcomes.

25 **Conclusion**

26 Based on our findings, aluminum chloride provides better hemostasis than epinephrine but was non-
27 significant compared to other hemostatic agents, and there was no significant difference between the other
28 hemostatic measures in endodontic surgery. Therefore, high-quality RCTs with a large sample size and
29 long follow-ups are required to compare the efficacy of hemostatic agents and to assess their effect on
30 healing. Based on the limited body of evidence, we cannot recommend using a specific hemostatic agent
31 during endodontic surgery at present.

1

2 **Author Contributions:**

3 Conceptualization: A.G.A.K.; Methodology: A.G.A.K., F.S.A., and A.S; Data collection: A.G.A.K.,
 4 E.M.S., M.M.A.H.; Data analysis: A.G.A.K., M.S.A.S.; Writing original draft preparation: A.G.A.K.,
 5 F.S.A., M.S.A.S.; Writing—review and editing: F.S.A., A.S., and A.G.A.K.; Supervision: A.S., F.S.A.
 6 All authors have read and agreed to the published version of the manuscript.

7

8 **Conflict of Interest Statement**

9 The authors deny any conflicts of interest related to this study

10 **Funding sources**

11 This research did not receive any specific grant from funding agencies in the public, commercial, or not-
 12 for-profit sectors.

13

14

15

Appendix Table S1: Search strategies

PubMed	((("Hemostatics"[Mesh] OR "Hemostatics" [Pharmacological Action]) AND ("Periapical Diseases/drug effects"[Mesh] OR "Periapical Diseases/drug therapy"[Mesh] OR "Periapical Diseases/surgery"[Mesh] OR "Periapical Diseases/therapy"[Mesh])) OR ("Periapical Tissue/drug effects"[Mesh] OR "Periapical Tissue/surgery"[Mesh])) OR ("Dental Pulp Diseases/drug effects"[Mesh] OR "Dental Pulp Diseases/drug therapy"[Mesh] OR "Dental Pulp Diseases/surgery"[Mesh])
Cochrane Library	#5 (#1 OR #2) AND (#3 OR #4) : #1 MeSH descriptor: [Hemostatics] explode all trees #2 MeSH descriptor: [Hemostasis] explode all trees #3 MeSH descriptor: [Endodontics] explode all trees #4 MeSH descriptor: [Periapical Diseases] explode all trees
Scopus	(("hemostasis") OR ("hemostatic agents") OR ("Surgical Hemostasis") OR ("Hemostatic Techniques") OR ("Hemostases")) AND (("endodontic surgery") OR ("apical surgery") OR ("periapical surgery") OR ("periradicular surgery") OR ("apicoectomy"))
Embase	#3 #2 AND #1 #2: 'hemostasis'/de OR 'hemostasis'/exp OR 'hemostatic agents' OR 'surgical hemostasis' OR 'hemostatic techniques'/de OR 'hemostatic techniques'/exp OR 'hemostases' #1: 'endodontic surgery'/de OR 'endodontic surgery'/exp OR 'apical surgery' OR 'periapical surgery' OR 'periradicular surgery' OR 'apicoectomy'/de OR 'apicoectomy'/exp

Web of Science	<p>#3 #2 AND #1</p> <p>#2: TS=("endodontic surgery") OR TS=("apical surgery") OR TS=("periapical surgery") OR TS=("periradicular surgery") OR TS=("apicoectomy") <i>Databases= WOS, BCI, KJD, MEDLINE, RSCI, SCIELO, ZOOREC</i> <i>Timespan=All years, Search language=Auto.</i></p> <p>#1: TS=("hemostasis") OR TS=("hemostatic agents") OR TS=("Surgical Hemostasis") OR TS=("Hemostatic Techniques") OR TS=("Hemostases") <i>Databases= WOS, BCI, KJD, MEDLINE, RSCI, SCIELO, ZOOREC</i> <i>Timespan=All years, Search language=Auto</i></p>
ProQuest	<p>AB("endodontic surgery") OR AB("apical surgery") OR AB("periapical surgery") OR AB("periradicular surgery") OR AB("apicoectomy") AND AB("hemostasis") OR AB("hemostatic agents") OR AB("Surgical Hemostasis") OR AB("Hemostatic Techniques") OR AB("Hemostases")</p>
EBSCOhost	<p>AB("endodontic surgery") OR AB("apical surgery") OR AB("periapical surgery") OR AB("periradicular surgery") OR AB("apicoectomy") AND AB("hemostasis") OR AB("hemostatic agents") OR AB("Surgical Hemostasis") OR AB("Hemostatic Techniques") OR AB("Hemostases")</p>

1

2

Appendix Table S2: Excluded studies after the full-text screening

Author (Year)	Title	DOI	Reason for exclusion
Selden (1970)	Bone wax as an effective hemostat in periapical surgery	10.1016/0030-4220(70)90095-2	Case series
Gutmann (1993)	Parameters of achieving quality anesthesia and hemostasis in surgical endodontics	-	Literature review
Lemon et al. (1993)	Ferric Sulfate Hemostasis: Effect on Osseous Wound Healing. I. Left In Situ for Maximum Exposure	10.1016/S0099-2399(06)80681-3	Animal study
Jeansonne et al. (1993)	Ferric Sulfate Hemostasis: Effect on Osseous Wound Healing, II, With Curettage and Irrigation	10.1016/S0099-2399(06)80682-5	Animal study
Witherspoon and Gutmann (1996)	Haemostasis in periradicular surgery	10.1111/j.1365-2591.1996.tb01360.x	Literature review
Kim and Rethnam (1997)	Hemostasis in endodontic microsurgery	-	Literature review
Sauveur et al. (1999)	The control of haemorrhage at the operative site during periradicular surgery	10.1046/j.1365-2591.1999.00191.x	Case report
Apaydin and Torabinejad (2004)	The effect of calcium sulfate on hard-tissue healing after periradicular surgery	10.1097/00004770-200401000-00003	Animal study

Vy et al. (2004)	Cardiovascular Effects and Efficacy of a Hemostatic Agent in Periradicular Surgery	10.1097/00004770-200406000-00001	Non-randomized trial
Von Arx et al. (2006)	Haemostatic agents used in periradicular surgery: an experimental study of their efficacy and tissue reactions	10.1111/j.1365-2591.2006.01152.x	Animal study
Jensen et al. (2010)	Haemostatic effect and tissue reactions of methods and agents used for haemorrhage control in apical surgery	10.1111/j.1365-2591.2009.01637.x	Animal study
Azargoon et al. (2011)	Assessment of hemostatic efficacy and osseous wound healing using HemCon dental dressing	10.1016/j.joen.2011.02.023	Animal study
Maestre-Ferrín et al. (2011)	Hemostatic agents used in apical surgery: a review.	10.4317/jced.3.e310	Literature review
Scarano et al. (2012)	Hemostasis Control in Endodontic Surgery: A Comparative Study of Calcium Sulfate versus Gauzes and versus Ferric Sulfate	10.1016/j.joen.2011.09.019	Non-randomized trial
Peñarrocha-Diago et al. (2012)	Pain and swelling after periapical surgery related to the hemostatic agent used: Anesthetic solution with vasoconstrictor or aluminum chloride	10.4317/medoral.17782	Observational study
Peñarrocha-Diago et al. (2013)	Influence of hemostatic agents upon the outcome of periapical surgery: dressings with anesthetic and vasoconstrictor or aluminum chloride	10.4317/medoral.18002	Retrospective study
Coaguila Llerena et al. (2015)	Agentes hemostáticos en cirugía periapical. Revisión de literatura Hemostatic agents in apical surgery. A review	-	Literature review & Non-English Study
Clé-Ovejero et al. (2016)	Haemostatic agents in apical surgery. A systematic review	10.4317/medoral.21109	Systematic review
Nabavizadeh et al. (2016)	Comparison of the Hemostatic Activity of Quercus persica Jaub. & Spach. (Oak) With Ferric Sulfate in Bony Crypts	10.1177/2156587215593378	Animal study
Mc Goldrick et al. (2017)	Trial finds better haemostasis with aluminium chloride during periapical surgery	10.1038/sj.ebd.6401240	Editorial
Menéndez Nieto et al. (2018)	New perspectives in periapical surgery: Hemostasis	-	Literature review
Brignardello-Petersen (2019)	There may be no differences in the success of periapical surgery when using aluminum chloride or epinephrine as hemostatic agent during surgery	10.1016/j.adaj.2018.09.013	Editorial
Mena-Álvarez et al. (2019)	Histological analysis of different local haemostatic agents used for periapical surgery: An experimental study with Sprague-Dawley rats	10.1111/aej.12332	Animal study
Phumpatrakom et al. (2020)	In vitro cytotoxicity of some hemostatic agents used in apicoectomy to human periodontal ligament and bone cells	10.4103/sej.sej_8_19	In-vitro study

1

2

3


1
2
3
4
5
6
7
8
9
10
11
12
13

14 **Appendix Table S3: Results of network meta-analysis**

Intervention	OR [95% CI]	Q statistics**		Rank	P-scores*
		Q	p-value		
Aluminum chloride	Reference			1 st	0.84 16
PTFE+ epinephrine	1.00 (0.34, 2.90)	0.29	0.59	2 nd	0.80 17
Electrocauterization	0.37 (0.12, 1.19)	---	---	3 th	0.344 18
Epinephrine	0.39 (0.22, 0.71)	0.03	0.87	4 th	0.34 19
Ferric sulfate	0.12 (0.00, 3.22)	---	---	5 th	0.18 20
Heterogeneity/ Inconsistency	$\tau^2 = 0$; $\tau = 0$; $I^2 = 0\%$ [0.0%; 35.2%]				21
P-value heterogeneity (within design)	0.85				22
P-value inconsistency (between design)	---				23
Number of studies	6				24
*Higher value of P-scores indicates better hemostatic efficacy					25
** Q statistics to assess homogeneity / consistency					


1
2
3
4
5
6
7
8
9
10
11
12

Journal Pre-proof



1

Appendix Figure S1: Forest plot visualizes the net-split results by summarizing the direct and indirect effect estimates in all comparisons




Appendix Figure S2: Comparison-adjusted Funnel Plot assesses the publication bias in the network meta-analysis and reveals the symmetry distribution between studies around the zero line.

Due to the limited number of comparisons, the p-value of Egger's Test is not available.

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Direct evidence proportion for each network estimate (random-effects model)



Appendix Figure S3: Direct-evidence plot shows the proportion of direct and indirect contributions in each comparison. Comparison with lower minimal parallelism values and more than two in Mean Path Length means that the results should be viewed with caution.

In NMA, Cautions should be taken when considering the results of these comparisons: Ferric sulfate vs. PTFE + epinephrine, and Ferric sulfate vs. Electrocauterization.

7

8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

References

1. Danin J, Linder LE, Lundqvist G, Ohlsson L, Ramskold LO, Stromberg T. Outcomes of periradicular surgery in cases with apical pathosis and untreated canals. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1999;87:227-232. doi: 10.1016/s1079-2104(99)70277-5.
2. Mulligan TW. Surgical endodontics. *Clin Tech Small Anim Pract.* 2001;16:186-197. doi: 10.1053/svms.2001.28023.
3. Eliyas S, Vere J, Ali Z, Harris I. Micro-surgical endodontics. *Br Dent J.* 2014;216:169-177. doi: 10.1038/sj.bdj.2014.142.
4. European Society of E. Quality guidelines for endodontic treatment: consensus report of the European Society of Endodontology. *Int Endod J.* 2006;39:921-930. doi: 10.1111/j.1365-2591.2006.01180.x.
5. von Arx T. Apical surgery: A review of current techniques and outcome. *Saudi Dent J.* 2011;23:9-15. doi: 10.1016/j.sdentj.2010.10.004.
6. Evans GE, Bishop K, Renton T. Update of guidelines for surgical endodontics - the position after ten years. *Br Dent J.* 2012;212:497-498. doi: 10.1038/sj.bdj.2012.418.
7. Penarrocha-Diago M, Maestre-Ferrin L, Penarrocha-Oltra D, von Arx T, Penarrocha-Diago M. Influence of hemostatic agents upon the outcome of periapical surgery: dressings with anesthetic and vasoconstrictor or aluminum chloride. *Med Oral Patol Oral Cir Bucal.* 2013;18:e272-278. doi: 10.4317/medoral.18002.
8. Penarrocha-Diago M, Menendez-Nieto I, Cervera-Ballester J, Maestre-Ferrin L, Blaya-Tarraga JA, Penarrocha-Oltra D. Influence of Hemostatic Agents in the Prognosis of Periapical Surgery: A Randomized Study of Epinephrine versus Aluminum Chloride. *J Endod.* 2018;44:1205-1209. doi: 10.1016/j.joen.2018.03.013.


- 1 9. Kim S, Rethnam S. Hemostasis in endodontic microsurgery. *Dent Clin North Am.* 1997;41:499-
2 511.
- 3 10. Kim S, Kratchman S. Modern endodontic surgery concepts and practice: a review. *J Endod.*
4 2006;32:601-623. doi: 10.1016/j.joen.2005.12.010.
- 5 11. Selden HS. Bone wax as an effective hemostat in periapical surgery. *Oral Surg Oral Med Oral*
6 *Pathol.* 1970;29:262-264. doi: 10.1016/0030-4220(70)90095-2.
- 7 12. Witherspoon DE, Gutmann JL. Haemostasis in periradicular surgery. *Int Endod J.* 1996;29:135-
8 149. doi: 10.1111/j.1365-2591.1996.tb01360.x.
- 9 13. Gutmann JL. Parameters of achieving quality anesthesia and hemostasis in surgical endodontics.
10 *Anesth Pain Control Dent.* 1993;2:223-226.
- 11 14. Scarano A, Artese L, Piattelli A, Carinci F, Mancino C, Iezzi G. Hemostasis control in
12 endodontic surgery: a comparative study of calcium sulfate versus gauzes and versus ferric
13 sulfate. *J Endod.* 2012;38:20-23. doi: 10.1016/j.joen.2011.09.019.
- 14 15. Sauveur G, Roth F, Sobel M, Boucher Y. The control of haemorrhage at the operative site during
15 periradicular surgery. *Int Endod J.* 1999;32:225-228. doi: 10.1046/j.1365-2591.1999.00191.x.
- 16 16. Vickers FJ, Baumgartner JC, Marshall G. Hemostatic efficacy and cardiovascular effects of
17 agents used during endodontic surgery. *J Endod.* 2002;28:322-323. doi: 10.1097/00004770-
18 200204000-00015.
- 19 17. Vy CH, Baumgartner JC, Marshall JG. Cardiovascular effects and efficacy of a hemostatic agent
20 in periradicular surgery. *J Endod.* 2004;30:379-383. doi: 10.1097/00004770-200406000-00001.
- 21 18. Lemon RR, Steele PJ, Jeansonne BG. Ferric sulfate hemostasis: effect on osseous wound healing.
22 Left in situ for maximum exposure. *J Endod.* 1993;19:170-173. doi: 10.1016/s0099-
23 2399(06)80681-3.
- 24 19. Menendez-Nieto I, Cervera-Ballester J, Maestre-Ferrin L, Blaya-Tarraga JA, Penarrocha-Oltra D,
25 Penarrocha-Diago M. Hemostatic Agents in Periapical Surgery: A Randomized Study of Gauze
26 Impregnated in Epinephrine versus Aluminum Chloride. *J Endod.* 2016;42:1583-1587. doi:
27 10.1016/j.joen.2016.08.005.
- 28 20. Penarrocha-Oltra D, Menendez-Nieto I, Cervera-Ballester J, Maestre-Ferrin L, Penarrocha-Diago
29 M, Penarrocha-Diago M. Aluminum Chloride versus Electrocauterization in Periapical Surgery:
30 A Randomized Controlled Trial. *J Endod.* 2019;45:89-93. doi: 10.1016/j.joen.2018.11.004.
- 31 21. Penarrocha-Oltra D, Soto-Penalozza D, Penarrocha-Diago M, Cervera-Ballester J, von Arx TDmd,
32 Penarrocha-Diago M. Hemostatic Agents in Endodontic Surgery: A Randomized Controlled Pilot
33 Study of Polytetrafluoroethylene Strips as an Adjunct to Epinephrine Impregnated Gauze Versus
34 Aluminum Chloride. *J Endod.* 2019;45:970-976. doi: 10.1016/j.joen.2019.04.011.
- 35 22. Penarrocha-Oltra D, Soto-Penalozza D, Penarrocha-Diago M, Cervera-Ballester J, Cabanes-
36 Gumbau G, Penarrocha-Diago M. Hemostatic agents in endodontic surgery of maxillary molars:
37 A randomized controlled pilot study of polytetrafluoroethylene (PTFE) strips as an adjunct to
38 epinephrine impregnated gauze versus aluminum chloride. *Med Oral Patol Oral Cir Bucal.*
39 2020;25:e634-e643. doi: 10.4317/medoral.23652.
- 40 23. Dias S, Caldwell DM. Network meta-analysis explained. *Arch Dis Child Fetal Neonatal Ed.*
41 2019;104:F8-F12. doi: 10.1136/archdischild-2018-315224.
- 42 24. Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Undertaking network meta- analyses.
43 *Cochrane Handbook for Systematic Reviews of Interventions.* 2019:285-320.

- 1 25. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-
2 analysis: many names, many benefits, many concerns for the next generation evidence synthesis
3 tool. *Res Synth Methods*. 2012;3:80-97. doi: 10.1002/jrsm.1037.
- 4 26. Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses
5 should be the highest level of evidence in treatment guidelines. *Eur Arch Psychiatry Clin*
6 *Neurosci*. 2016;266:477-480. doi: 10.1007/s00406-016-0715-4.
- 7 27. Faltinsen EG, Storebo OJ, Jakobsen JC, Boesen K, Lange T, Gluud C. Network meta-analysis:
8 the highest level of medical evidence? *BMJ Evid Based Med*. 2018;23:56-59. doi:
9 10.1136/bmjebm-2017-110887.
- 10 28. Nagendrababu V, Pulikkotil SJ, Suresh A, Veetil SK, Bhatia S, Setzer FC. Efficacy of local
11 anaesthetic solutions on the success of inferior alveolar nerve block in patients with irreversible
12 pulpitis: a systematic review and network meta-analysis of randomized clinical trials. *Int Endod*
13 *J*. 2019;52:779-789. doi: 10.1111/iej.13072.
- 14 29. Zanjir M, Lighvan NL, Yarascavitch C, Beyene J, Shah PS, Azarpazhooh A. Efficacy and Safety
15 of Pulpal Anesthesia Strategies during Endodontic Treatment of Permanent Mandibular Molars
16 with Symptomatic Irreversible Pulpitis: A Systematic Review and Network Meta-analysis. *J*
17 *Endod*. 2019;45:1435-1464 e1410. doi: 10.1016/j.joen.2019.09.002.
- 18 30. Pulikkotil SJ, Nagendrababu V, Veetil SK, Jinatongthai P, Setzer FC. Effect of oral
19 premedication on the anaesthetic efficacy of inferior alveolar nerve block in patients with
20 irreversible pulpitis - A systematic review and network meta-analysis of randomized controlled
21 trials. *Int Endod J*. 2018;51:989-1004. doi: 10.1111/iej.12912.
- 22 31. Nagendrababu V, Pulikkotil SJ, Jinatongthai P, Veetil SK, Teerawattanapong N, Gutmann JL.
23 Efficacy and Safety of Oral Premedication on Pain after Nonsurgical Root Canal Treatment: A
24 Systematic Review and Network Meta-analysis of Randomized Controlled Trials. *J Endod*.
25 2019;45:364-371. doi: 10.1016/j.joen.2018.10.016.
- 26 32. Zanjir M, Sgro A, Lighvan NL, et al. Efficacy and Safety of Postoperative Medications in
27 Reducing Pain after Nonsurgical Endodontic Treatment: A Systematic Review and Network
28 Meta-analysis. *J Endod*. 2020;46:1387-1402 e1384. doi: 10.1016/j.joen.2020.07.002.
- 29 33. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of
30 systematic reviews incorporating network meta-analyses of health care interventions: checklist
31 and explanations. *Ann Intern Med*. 2015;162:777-784. doi: 10.7326/M14-2385.
- 32 34. Khater AGA, Al-hamed FS, Safwat EM, et al. Efficacy of hemostatic agents in endodontic
33 surgery: A protocol of systematic review and network meta-analysis. *Inplasy protocol*.
34 2021;202120038. doi: 10.37766/inplasy2021.2.0038.
- 35 35. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in
36 randomised trials. *BMJ*. 2019;366:l4898. doi: 10.1136/bmj.l4898. PMID: 31462531.
- 37 36. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web
38 app for visualizing risk-of-bias assessments. *Res Synth Methods*. 2021;12:55-61. doi:
39 10.1002/jrsm.1411.
- 40 37. Rucker G, Krahn U, König J, Efthimiou O, Schwarzer G. Package 'netmeta'. *Network Meta-*
41 *Analysis using Frequentist Methods (Version 1.2-1)*2020.
- 42 38. Harrer M, Cuijpers P, Furukawa T, Ebert D. Doing meta-analysis in R: a hands-on guide.
43 *PROTECT Lab Erlangen*. 2019.
- 44 39. Team RC. R: A language and environment for statistical computing. 2020.

- 1 40. Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-
2 analyses. *BMC Med Res Methodol*. 2013;13:35. doi: 10.1186/1471-2288-13-35.
- 3 41. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without
4 resampling methods. *BMC Med Res Methodol*. 2015;15:58. doi: 10.1186/s12874-015-0060-8.
- 5 42. CINeMA: Confidence in Network Meta- Analysis [Software]. Institute of Social and Preventive
6 Medicine, University of Bern, Retrieved from: <https://cinema.ispm.unibe.ch/>; 2017.
- 7 43. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: An approach for assessing
8 confidence in the results of a network meta-analysis. *PLoS Med*. 2020;17:e1003082. doi:
9 10.1371/journal.pmed.1003082.
- 10 44. Papakonstantinou T, Nikolakopoulou A, Higgins JP, Egger M, Salanti G. CINeMA: Software for
11 semiautomated assessment of the confidence in the results of network meta- analysis. *Campbell*
12 *Systematic Reviews*. 2020;16:e1080. doi.org/10.1002/cl2.1080.
- 13 45. Apaydin ES, Torabinejad M. The effect of calcium sulfate on hard-tissue healing after
14 periradicular surgery. *J Endod*. 2004;30:17-20. doi: 10.1097/00004770-200401000-00003.
- 15 46. Azargoon H, Williams BJ, Solomon ES, Kessler HP, He J, Spears R. Assessment of hemostatic
16 efficacy and osseous wound healing using HemCon dental dressing. *J Endod*. 2011;37:807-811.
17 doi: 10.1016/j.joen.2011.02.023.
- 18 47. Brignardello-Petersen R. There may be no differences in the success of periapical surgery when
19 using aluminum chloride or epinephrine as hemostatic agent during surgery. *J Am Dent Assoc*.
20 2019;150:e26. doi: 10.1016/j.adaj.2018.09.013.
- 21 48. Cle-Ovejero A, Valmaseda-Castellon E. Haemostatic agents in apical surgery. A systematic
22 review. *Med Oral Patol Oral Cir Bucal*. 2016;21:e652-657. doi: 10.4317/medoral.21109.
- 23 49. Coaguila Llerena H, Mendiola Aquino C. Agentes hemostáticos en cirugía periapical: Revisión
24 de literatura. *Revista Estomatológica Herediana*. 2015;25:318-326.
- 25 50. Jensen SS, Yazdi PM, Hjorting-Hansen E, Bosshardt DD, von Arx T. Haemostatic effect and
26 tissue reactions of methods and agents used for haemorrhage control in apical surgery. *Int Endod*
27 *J*. 2010;43:57-63. doi: 10.1111/j.1365-2591.2009.01637.x.
- 28 51. Maestre Ferrín L, Peñarrocha Diago M. Hemostatic agents used in apical surgery: A review.
29 2011.
- 30 52. Mc Goldrick N, Ross C, Nelson J. Trial finds better haemostasis with aluminium chloride during
31 periapical surgery. *Evid Based Dent*. 2017;18:50-51. doi:10.1038/sj.ebd.6401240. PMID:
32 28642552.
- 33 53. Mena-Alvarez J, Quispe-Lopez N, Zubizarreta-Macho A, Rico-Romano C, Rodero-Villanueva R,
34 Fernandez-Acenero MJ. Histological analysis of different local haemostatic agents used for
35 periapical surgery: An experimental study with Sprague-Dawley rats. *Aust Endod J*. 2019;45:357-
36 364. doi: 10.1111/aej.12332.
- 37 54. Nabavizadeh MR, Zargaran A, Moazami F, et al. Comparison of the Hemostatic Activity of
38 *Quercus persica* Jaub. & Spach. (Oak) With Ferric Sulfate in Bony Crypts. *J Evid Based*
39 *Complementary Altern Med*. 2016;21:34-38. doi: 10.1177/2156587215593378.
- 40 55. Penarrocha-Diago M, Maestre-Ferrin L, Penarrocha-Oltra D, Gay-Escoda C, von-Arx T,
41 Penarrocha-Diago M. Pain and swelling after periapical surgery related to the hemostatic agent
42 used: anesthetic solution with vasoconstrictor or aluminum chloride. *Med Oral Patol Oral Cir*
43 *Bucal*. 2012;17:e594-600. doi: 10.4317/medoral.17782.

- 1 56. Phumpatrakom P, Ariyakriangkai W, Srisuwan T, Louwakul P. In vitro cytotoxicity of some
2 hemostatic agents used in apicoectomy to human periodontal ligament and bone cells. *Saudi*
3 *Endodontic Journal*. 2020;10:21. doi: 10.4103/sej.sej_8_19.
- 4 57. von Arx T, Jensen SS, Hanni S, Schenk RK. Haemostatic agents used in periradicular surgery: an
5 experimental study of their efficacy and tissue reactions. *Int Endod J*. 2006;39:800-808. doi:
6 10.1111/j.1365-2591.2006.01152.x.
- 7 58. Menendez Nieto I, Cervera Ballester J, Penarrocha Diago M, Penarrocha Oltra D. New
8 perspectives in periapical surgery: Hemostasis. *J. Oral Sci. Rehabil*. 2018;4.
- 9 59. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of
10 evidence from a network meta-analysis. *PLoS One*. 2014;9:e99682.
- 11 60. Nouri S, Sharif MR, Panahi Y, Ghanei M, Jamali B. Efficacy and safety of aluminum chloride in
12 controlling external hemorrhage: an animal model study. *Iran Red Crescent Med J*.
13 2015;17:e19714. doi: 10.1371/journal.pone.0099682.
- 14 61. Nouri S, Amirbeigy M, Hosseinpour M, Abdorrahim K, Sharif M, Amirbeigy M. Evaluation of
15 the Hemostatic Effect of Ferric Sulphate in Controlling External Bleeding in Mouse at Kashan
16 University of Medical Sciences. *Iran J Surg*. 2012;22:1-8. doi: 10.5812/ircmj.19714.
- 17 62. Sattar MM, Patel M, Alani A. Clinical applications of polytetrafluoroethylene (PTFE) tape in
18 restorative dentistry. *Br Dent J*. 2017;222:151-158. doi: 10.1038/sj.bdj.2017.110.
- 19 63. Tan X, Rodrigue D. A Review on Porous Polymeric Membrane Preparation. Part II: Production
20 Techniques with Polyethylene, Polydimethylsiloxane, Polypropylene, Polyimide, and
21 Polytetrafluoroethylene. *Polymers (Basel)*. 2019;11. doi: 10.3390/polym11081310.
- 22 64. Ratner BD, Hoffman AS, Schoen FJ, Lemons JE. *Biomaterials science: an introduction to*
23 *materials in medicine*: Elsevier; 2004.
- 24 65. Rae P, Brown E. The properties of poly (tetrafluoroethylene)(PTFE) in tension. *Polymer*.
25 2005;46:8128-8140. doi: 10.1016/j.polymer.2005.06.120.
- 26 66. Ingle JI, Baumgartne JC. *Ingle's endodontics 6*: BC Decker; Maidenhead: McGraw-Hill
27 Education [distributor]; 2008.
- 28 67. Pecora G, Baek SH, Rethnam S, Kim S. Barrier membrane techniques in endodontic
29 microsurgery. *Dent Clin North Am*. 1997;41:585-602.
- 30 68. Strocchi R, Orsini G, Iezzi G, et al. Bone regeneration with calcium sulfate: evidence for
31 increased angiogenesis in rabbits. *J Oral Implantol*. 2002;28:273-278. doi: 10.1563/1548-
32 1336(2002)028<0273:BRWCSE>2.3.CO;2.
- 33 69. Scarano A, Degidi M, Iezzi G, et al. Maxillary sinus augmentation with different biomaterials: a
34 comparative histologic and histomorphometric study in man. *Implant Dent*. 2006;15:197-207.
35 doi: 10.1097/01.id.0000220120.54308.f3.
- 36 70. Scarano A, Sinjari B, Murmura G, et al. Hemostasis control in dental extractions in patients
37 receiving oral anticoagulant therapy: an approach with calcium sulfate. *J Craniofac Surg*.
38 2014;25:843-846. doi: 10.1097/SCS.0000000000000824.
- 39 71. Scarano A, Carinci F, Cimorelli E, Quaranta M, Piattelli A. Application of calcium sulfate in
40 surgical-orthodontic treatment of impacted teeth: a new procedure to control hemostasis. *J Oral*
41 *Maxillofac Surg*. 2010;68:964-968. doi: 10.1016/j.joms.2009.12.020.
- 42 72. James G. Simplified techniques in surgical periapical treatment. *Dental Clinics of North America*:
43 WB SAUNDERS CO INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300,
44 PHILADELPHIA ...; 1963:375.

- 1 **73.** Gogerty JH, Strand HA, Ogilvie AL, Dille JM. Vasopressor effects of topical epinephrine in
 2 certain dental procedures. *Oral Surg Oral Med Oral Pathol.* 1957;10:614-622. doi:
 3 [10.1016/s0030-4220\(57\)80009-7](https://doi.org/10.1016/s0030-4220(57)80009-7).
- 4 **74.** Besner E. Systemic effects of racemic epinephrine when applied to the bone cavity during
 5 periapical surgery. *Va Dent J.* 1972;49:9-12.
- 6 **75.** Costich E, Hayward J. Hemorrhage: its prevention and therapeutic control. *Dent Clin North Am.*
 7 1958;2:195-210.
- 8 **76.** Eriksson A, Albrektsson T, Grane B, McQueen D. Thermal injury to bone. A vital-microscopic
 9 description of heat effects. *Int J Oral Surg.* 1982;11:115-121. doi: [10.1016/s0300-
 10 9785\(82\)80020-3](https://doi.org/10.1016/s0300-9785(82)80020-3).
- 11 **77.** Woody RD, Miller A, Staffanou RS. Review of the pH of hemostatic agents used in tissue
 12 displacement. *J Prosthet Dent.* 1993;70:191-192. doi: [10.1016/0022-3913\(93\)90018-j](https://doi.org/10.1016/0022-3913(93)90018-j).
- 13 **78.** Jeansonne BG, Boggs WS, Lemon RR. Ferric sulfate hemostasis: effect on osseous wound
 14 healing. II. With curettage and irrigation. *J Endod.* 1993;19:174-176. doi: [10.1016/S0099-
 15 2399\(06\)80682-5](https://doi.org/10.1016/S0099-2399(06)80682-5).



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Journal Pre-proof

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19


Figure 1: PRISMA flow diagram illustrates the process of literature search and study selection.

	Risk of bias domains					Overall
	D1	D2	D3	D4	D5	
Vickers et al. (2002)	-	-	+	-	-	X
Menendez-Nieto et al. (2016)	+	+	+	+	-	-
Penarrocha-Diago et al. (2018)	+	+	+	+	-	-
Penarrocha-Oltra et al. (2019) (1)	+	+	+	+	-	-
Penarrocha-Oltra et al. (2019) (2)	+	+	+	+	-	-
Penarrocha-Oltra et al. (2020)	+	+	+	+	-	-


Domains:
D1: Bias arising from the randomization process
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

Judgement
X High
- Some concerns
+ Low

1 **Figure 2:** A) Risk of bias summary indicates each risk of bias for each included study.



2
3
4



1

2 **Figure 2:** B) Risk of bias graph summarized each risk of bias item presented as percentages across all
3 included studies.

4

5 **Figure 3:** Network plot of hemostatic agents used in endodontic surgery. The node's size represents the
6 number of studies, while the width of the edges represents the sample size, and its color represents the
7 risk of bias.

8


9

10

11

1
2
3
4
5
6
7
8
9
10
11
12
13
14

Journal Pre-proof



1 **Figure 4:** Forest plot showed direct comparisons (pairwise meta-analysis) of different treatments in
 2 terms of hemostatic efficacy.

3
 4
 5
 6
 7
 8
 9

Table 0: Main characteristics of the included studies

Authors (Years) Country	Study design Location Operator	Hemostatic agent	Participants	Hemostatic efficacy	Funding
-------------------------------	--------------------------------------	------------------	--------------	---------------------	---------

		<i>Experimental</i>	<i>Comparator</i>	<i>Age Mean ±SD (Medical status)</i>	<i>Sample size (M/F ratio)</i>	<i>N. Exp.</i>	<i>N. Com.</i>	<i>Exp.</i>	<i>Com.</i>	
Vickers et al. (2002) ¹⁶ USA	RCT University Endodontic resident	Racemic-epinephrine cotton pellets (Racellet #3, Pascal Company, Inc., Bellevue, WA)	20% Ferric sulfate (Viscostat, Ultradent, South Jordan, UT)	NR (ASA I or II)	39 (NR)	17	16	100%	93.75%	NR
Benendez-Nieto et al. (2016) ¹⁹ Spain	RCT University Oral surgeon	Aluminum chloride (ExpasyI™, Produits Dentaires Pierre Rolland, Merignac, France)	Gauzes with epinephrine (B-Braun, 1 mg/mL; Rubi, Barcelona, Spain)	47.5 ±15 (NR)	99 (36:63)	51	48	72.5%	52.1%	None
Benarrocha-Diago et al. (2018) ⁸ Spain	RCT University Oral surgeon	Aluminum chloride (ExpasyI™, Produits Dentaires Pierre Rolland, Merignac, France)	Gauzes with epinephrine (B-Braun, 1 mg/mL; Rubi, Barcelona, Spain)	47.5 ±15 (NR)	95 (67:28)	50	45	72%	48.9%	None
Benarrocha-Oltra et al. (2019) (1) ²⁰ Spain	RCT University Oral surgeon	Aluminum chloride (ExpasyI™, Produits Dentaires Pierre Rolland, Merignac, France)	Electrocauterization (Ball electrode; Servotome Classic; Satelec/ Acteon, Norwich, England)	46 ±15.4 (NR)	60 (19:41)	30	30	80%	60%	None
Benarrocha-Oltra et al. (2019) (2) ²¹ Spain	RCT University Oral surgeon	Aluminum chloride (ExpasyI™, Produits Dentaires Pierre Rolland, Merignac, France)	PTFE strips+ epinephrine	51.6 ±14.8 (ASA I or II)	30 (16:14)	15	15	60%	53.3%	None
Benarrocha-Oltra et al. (2020) ²² Spain	RCT University Oral surgeon	Aluminum chloride (ExpasyI™, Produits Dentaires Pierre Rolland, Merignac, France)	PTFE strips+ epinephrine	48 ±10.8 (ASA I or II)	30 (8: 22)	15	15	66.7%	73.3%	None

***Abbreviations:** RCT, randomized clinical trial; PTFE, Polytetrafluoroethylene; ASA, American Society of Anesthesiologists; M, male; F, female; NR, not reported.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17**Table 2: League table of network meta-analysis of hemostatic efficacy**

18

<i>Aluminum chloride</i>	2.67 (0.84, 8.46)	2.55 (1.41, 4.64)	8.65 (0.31, 240.92)	1.00 (0.35, 2.90)
--------------------------	-------------------	--------------------------	---------------------	-------------------

0.3750 (0.12, 1.19)	Electrocauterization	0.9579 (0.26, 3.51)	3.2446 (0.10, 109.77)	0.3752 (0.08, 1.80)
0.39 (0.22, 1.33)	1.04 (0.28, 89.37)	Epinephrine	3.39 (0.13, 3.83)	0.39 (0.12, 0.71)
0.12 (0.00, 3.22)	0.31 (0.01, 10.43)	0.30 (0.01, 7.79)	Ferric sulfate	0.12 (0.00, 3.80)
1.00 (0.34, 2.90)	2.67 (0.55, 12.82)	2.55 (0.75, 8.65)	8.65 (0.26, 284.31)	PTFE+ epinephrine

The cells contain the odds ratio (OR, 95% confidence interval) of the treatment. Odds ratios <1 favor the intervention specified in the row. The bolded values are statistically significant. Comparisons between treatments should be read from left to right and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment.

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Journal Pre-proof

Table 8: Certainty of evidence

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
<i>Mixed evidence</i>								
Aluminum chloride vs. Electrocauterization	1	Some concerns	Undetected	No concerns	Some concerns	Some concerns	Major concerns	<i>Very low</i>
Aluminum chloride vs. Epinephrine	2	Some concerns	Undetected	No concerns	No concerns	Major concerns	Major concerns	<i>Very low</i>
Aluminum chloride vs. PTFE+ epinephrine	2	Some concerns	Undetected	No concerns	Major concerns	No concerns	Major concerns	<i>Very low</i>
<i>Indirect evidence</i>								
Aluminum chloride vs. Ferric sulfate	--	Major concerns	Undetected	No concerns	Major concerns	No concerns	Major concerns	<i>Very low</i>

1

2

3